Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response

J. Kirchheiner, K. Nickchen, M. Bauer, M. L. Wong, J. Licinio, I. Roots, J. Brockmöller

Research output: Contribution to journalReview article

556 Citations (Scopus)

Abstract

Genetic factors contribute to the phenotype of drug response. We systematically analyzed all available pharmacogenetic data from Medline databases (1970-2003) on the impact that genetic polymorphisms have on positive and adverse reactions to antidepressants and antipsychotics. Additionally, dose adjustments that would compensate for genetically caused differences in blood concentrations were calculated. To study pharmacokinetic effects, data for 36 antidepressants were screened. We found that for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and that in 14 drugs such genetic variation would require at least doubling of the dose in extensive metabolizers in comparison to poor metabolizers. Data for 38 antipsychotics were examined: for 13 of those CYP2D6 and CYP2C19 genotype was of relevance. To study the effects of genetic variability on pharmacodynamic pathways, we reviewed 80 clinical studies on polymorphisms in candidate genes, but those did not for the most part reveal significant associations between neurotransmitter receptor and transporter genotypes and therapy response or adverse drug reactions. In addition associations found in one study could not be replicated in other studies. For this reason, it is not yet possible to translate pharmacogenetic parameters fully into therapeutic recommendations. At present, antidepressant and antipsychotic drug responses can best be explained as the combinatorial outcome of complex systems that interact at multiple levels. In spite of these limitations, combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.

LanguageEnglish
Pages442-473
Number of pages32
JournalMolecular Psychiatry
Volume9
Issue number5
DOIs
Publication statusPublished - 1 May 2004

Keywords

  • Antidepressant
  • Antipsychotic
  • Cytochrome P450
  • Dose recommendation
  • Pharmacogenetics
  • Pharmacogenomics

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M. L., Licinio, J., Roots, I., & Brockmöller, J. (2004). Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 9(5), 442-473. https://doi.org/10.1038/sj.mp.4001494
Kirchheiner, J. ; Nickchen, K. ; Bauer, M. ; Wong, M. L. ; Licinio, J. ; Roots, I. ; Brockmöller, J. / Pharmacogenetics of antidepressants and antipsychotics : The contribution of allelic variations to the phenotype of drug response. In: Molecular Psychiatry. 2004 ; Vol. 9, No. 5. pp. 442-473.
@article{8329a2ca25d54131a532a71996e1383d,
title = "Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response",
abstract = "Genetic factors contribute to the phenotype of drug response. We systematically analyzed all available pharmacogenetic data from Medline databases (1970-2003) on the impact that genetic polymorphisms have on positive and adverse reactions to antidepressants and antipsychotics. Additionally, dose adjustments that would compensate for genetically caused differences in blood concentrations were calculated. To study pharmacokinetic effects, data for 36 antidepressants were screened. We found that for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and that in 14 drugs such genetic variation would require at least doubling of the dose in extensive metabolizers in comparison to poor metabolizers. Data for 38 antipsychotics were examined: for 13 of those CYP2D6 and CYP2C19 genotype was of relevance. To study the effects of genetic variability on pharmacodynamic pathways, we reviewed 80 clinical studies on polymorphisms in candidate genes, but those did not for the most part reveal significant associations between neurotransmitter receptor and transporter genotypes and therapy response or adverse drug reactions. In addition associations found in one study could not be replicated in other studies. For this reason, it is not yet possible to translate pharmacogenetic parameters fully into therapeutic recommendations. At present, antidepressant and antipsychotic drug responses can best be explained as the combinatorial outcome of complex systems that interact at multiple levels. In spite of these limitations, combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.",
keywords = "Antidepressant, Antipsychotic, Cytochrome P450, Dose recommendation, Pharmacogenetics, Pharmacogenomics",
author = "J. Kirchheiner and K. Nickchen and M. Bauer and Wong, {M. L.} and J. Licinio and I. Roots and J. Brockm{\"o}ller",
year = "2004",
month = "5",
day = "1",
doi = "10.1038/sj.mp.4001494",
language = "English",
volume = "9",
pages = "442--473",
journal = "Molecular psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "5",

}

Kirchheiner, J, Nickchen, K, Bauer, M, Wong, ML, Licinio, J, Roots, I & Brockmöller, J 2004, 'Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response', Molecular Psychiatry, vol. 9, no. 5, pp. 442-473. https://doi.org/10.1038/sj.mp.4001494

Pharmacogenetics of antidepressants and antipsychotics : The contribution of allelic variations to the phenotype of drug response. / Kirchheiner, J.; Nickchen, K.; Bauer, M.; Wong, M. L.; Licinio, J.; Roots, I.; Brockmöller, J.

In: Molecular Psychiatry, Vol. 9, No. 5, 01.05.2004, p. 442-473.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pharmacogenetics of antidepressants and antipsychotics

T2 - Molecular psychiatry

AU - Kirchheiner, J.

AU - Nickchen, K.

AU - Bauer, M.

AU - Wong, M. L.

AU - Licinio, J.

AU - Roots, I.

AU - Brockmöller, J.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Genetic factors contribute to the phenotype of drug response. We systematically analyzed all available pharmacogenetic data from Medline databases (1970-2003) on the impact that genetic polymorphisms have on positive and adverse reactions to antidepressants and antipsychotics. Additionally, dose adjustments that would compensate for genetically caused differences in blood concentrations were calculated. To study pharmacokinetic effects, data for 36 antidepressants were screened. We found that for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and that in 14 drugs such genetic variation would require at least doubling of the dose in extensive metabolizers in comparison to poor metabolizers. Data for 38 antipsychotics were examined: for 13 of those CYP2D6 and CYP2C19 genotype was of relevance. To study the effects of genetic variability on pharmacodynamic pathways, we reviewed 80 clinical studies on polymorphisms in candidate genes, but those did not for the most part reveal significant associations between neurotransmitter receptor and transporter genotypes and therapy response or adverse drug reactions. In addition associations found in one study could not be replicated in other studies. For this reason, it is not yet possible to translate pharmacogenetic parameters fully into therapeutic recommendations. At present, antidepressant and antipsychotic drug responses can best be explained as the combinatorial outcome of complex systems that interact at multiple levels. In spite of these limitations, combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.

AB - Genetic factors contribute to the phenotype of drug response. We systematically analyzed all available pharmacogenetic data from Medline databases (1970-2003) on the impact that genetic polymorphisms have on positive and adverse reactions to antidepressants and antipsychotics. Additionally, dose adjustments that would compensate for genetically caused differences in blood concentrations were calculated. To study pharmacokinetic effects, data for 36 antidepressants were screened. We found that for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and that in 14 drugs such genetic variation would require at least doubling of the dose in extensive metabolizers in comparison to poor metabolizers. Data for 38 antipsychotics were examined: for 13 of those CYP2D6 and CYP2C19 genotype was of relevance. To study the effects of genetic variability on pharmacodynamic pathways, we reviewed 80 clinical studies on polymorphisms in candidate genes, but those did not for the most part reveal significant associations between neurotransmitter receptor and transporter genotypes and therapy response or adverse drug reactions. In addition associations found in one study could not be replicated in other studies. For this reason, it is not yet possible to translate pharmacogenetic parameters fully into therapeutic recommendations. At present, antidepressant and antipsychotic drug responses can best be explained as the combinatorial outcome of complex systems that interact at multiple levels. In spite of these limitations, combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.

KW - Antidepressant

KW - Antipsychotic

KW - Cytochrome P450

KW - Dose recommendation

KW - Pharmacogenetics

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=3142519666&partnerID=8YFLogxK

U2 - 10.1038/sj.mp.4001494

DO - 10.1038/sj.mp.4001494

M3 - Review article

VL - 9

SP - 442

EP - 473

JO - Molecular psychiatry

JF - Molecular psychiatry

SN - 1359-4184

IS - 5

ER -